XOM

161.17

+0.95%↑

CVX

204.7

+1.5%↑

SHEL.US

90.76

+0.32%↑

TTE.FR

76.12

-1.12%↓

COPNY

127.33

+0.39%↑

XOM

161.17

+0.95%↑

CVX

204.7

+1.5%↑

SHEL.US

90.76

+0.32%↑

TTE.FR

76.12

-1.12%↓

COPNY

127.33

+0.39%↑

XOM

161.17

+0.95%↑

CVX

204.7

+1.5%↑

SHEL.US

90.76

+0.32%↑

TTE.FR

76.12

-1.12%↓

COPNY

127.33

+0.39%↑

XOM

161.17

+0.95%↑

CVX

204.7

+1.5%↑

SHEL.US

90.76

+0.32%↑

TTE.FR

76.12

-1.12%↓

COPNY

127.33

+0.39%↑

XOM

161.17

+0.95%↑

CVX

204.7

+1.5%↑

SHEL.US

90.76

+0.32%↑

TTE.FR

76.12

-1.12%↓

COPNY

127.33

+0.39%↑

Search

Core Natural Resources Inc

Cerrado

102.66 -3.98

Resumen

Variación precio

24h

Actual

Mínimo

100.12

Máximo

105.44

Métricas clave

By Trading Economics

Ingresos

-111M

-79M

Ventas

40M

1B

P/B

Media del Sector

37.118

66.822

BPA

-1.54

Rentabilidad por dividendo

0.4

Margen de beneficios

-7.576

Empleados

4,850

EBITDA

-89M

51M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+23.54% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.40%

3.56%

Próximas Ganancias

7 may 2026

Fecha Próximo Dividendo

12 jun 2026

Próxima Fecha de Ex Dividendo

29 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

314M

5B

Apertura anterior

106.64

Cierre anterior

102.66

Core Natural Resources Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 mar 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar 2026, 22:55 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mar 2026, 21:51 UTC

Adquisiciones, fusiones, absorciones

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mar 2026, 23:59 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

23 mar 2026, 23:59 UTC

Charlas de Mercado

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mar 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mar 2026, 23:37 UTC

Charlas de Mercado

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mar 2026, 22:42 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Global Equities Roundup: Market Talk

23 mar 2026, 22:42 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mar 2026, 22:40 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar 2026, 22:23 UTC

Charlas de Mercado

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mar 2026, 22:22 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar 2026, 22:21 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar 2026, 22:21 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar 2026, 22:20 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar 2026, 22:20 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar 2026, 22:19 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar 2026, 22:19 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mar 2026, 22:18 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mar 2026, 22:15 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mar 2026, 22:08 UTC

Charlas de Mercado

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mar 2026, 21:42 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

23 mar 2026, 21:42 UTC

Charlas de Mercado

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mar 2026, 21:32 UTC

Ganancias

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mar 2026, 21:32 UTC

Ganancias

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mar 2026, 21:32 UTC

Ganancias

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mar 2026, 21:10 UTC

Noticias de Eventos Importantes

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mar 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

23 mar 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

23 mar 2026, 20:50 UTC

Charlas de Mercado
Ganancias
Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Core Natural Resources Inc previsión

Precio Objetivo

By TipRanks

23.54% repunte

Estimación a 12 Meses

Media 132.4 USD  23.54%

Máximo 158 USD

Mínimo 109 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Core Natural Resources Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

5

Comprar

0

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

help-icon Live chat